Maurizio Zangari, M.D.


Professor of Medicine

Director of Myeloma Bone Disease Research

M.D., University of Padua, Padua, Italy

Fellowship, Bone Marrow Transplantation, Mount Sinai Hospital, New York, NY

Fellowship, Hematology, Mount Sinai Hospital, New York, NY

Residency, Wykoff Heights Medical Center, Brooklyn, NY


American Society of Hematology, Italian Medical Association

Research Interest:

Myeloma Bone Disease

Selected Publications:

Zangari M, Fink L, Zhan F, Tricot G. (2011). Low Venous Thromboembolic Risk With Bortezomib in Multiple Myeloma and Potential Protective Effect With Thalidomide/Lenalidomide-based Therapy: Review of Data From Phase 3 Trials and Studies of Novel Combination Regimens. Clin Lymphoma Myeloma Leuk, 11(2), 228-36.

Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, Esseltine D, Tricot G. (2011). A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica, 96(2), 333-6.

Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu Chunjiao, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G, Zhan F. (2010). Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. OncoTarget, 1(1), 22-33.

Zangari M, van Rhee F, Anaissie E, Pineda-Roman M, Haessler J, Crowley J, Barlogie B. (2008). Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol, 141(4), 433-44.

Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, Crowley J, Shaughnessy JD Jr, Barlogie B. (2008). Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol, 140(6), 625-34.

Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. (2005). Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol, 131(1), 71-3.